Practice

Dr Fran Gregory Discusses the Unique Requirements for Handling Biosimilars

June 18th 2023

By Pearl Steinzor

Video

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how specialty pharmacists manage inventory, storage, and handling of biosimilars.

Increased Competition Is Lowering Trastuzumab Prices

June 14th 2023

By Skylar Jeremias

Article

After 8 years of trastuzumab biosimilar competition and slow uptake, a new report shows that trastuzumab biosimilar discounts from the reference product (Herceptin) doubled between 2019 and 2022.

Nocebo Effect Leads to Switched Patients Reporting Greater Disease Severity, Poorer Quality of Life vs Nonswitched Patients

June 13th 2023

By Deana Ferreri, PhD

Article

A survey of patients with rheumatoid arthritis found that those who had switched to an adalimumab biosimilar reported higher disease severity, poorer treatment adherence, and poorer quality of life compared with patients who stayed on the reference product, highlighting the dangers of the nocebo effect.

What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends

May 28th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.

Dr Fran Gregory: What Can We Learn From Biosimilar Use in Other Countries?

May 21st 2023

By Pearl Steinzor

Video

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how the use of biosimilars in other countries strengthens the acceptance and approval of these products in the United States.

Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings

May 14th 2023

By Skylar Jeremias

Article

In light of 2 blockbuster originators, namely Humira (adalimumab) and Stelara (ustekinumab), losing market exclusivity in 2023, 3 doctors penned supplement in The American Journal of Managed Care®. On this episode, Vibeke Strand, MD, one of the co-authors, explored how health systems can take charge and boost biosimilar adoption.

Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry

May 11th 2023

By Skylar Jeremias

Article

The 2023 Asembia Specialty Pharmacy Summit featured Juliana (Julie) Reed, executive director of the Biosimilars Forum, who spoke on the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States.

Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology

May 9th 2023

By Skylar Jeremias

Article

Colby Evans, MD, a dermatologist and co-author of an American Journal of Managed Care® supplement “Biosimilars for Immune-Mediated Inflammatory Diseases: 2022 Update" shares the managed care perspective on using biosimilars to treat inflammatory conditions.

RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator

May 8th 2023

By Deana Ferreri, PhD

Article

In a study including 2 years of real-world evidence (RWE), patients with rheumatoid arthritis (RA) who were switched from originator rituximab (Rituxan) to GP2013, a rituximab biosimilar, experienced positive results and maintained clinical outcomes.

Long-term Phase 3 Results Show Similar Efficacy, Cardiac Safety of SB3 vs Herceptin

May 6th 2023

By Deana Ferreri, PhD

Article

The authors of what they say is the largest and longest follow-up study comparing the trastuzumab biosimilar SB3 to the reference product (Herceptin) in HER2-positive breast cancer found “no clinically meaningful difference” between the biosimilar and the reference product.